ANI Pharmaceuticals Acquires Novitium Pharma for $163.5M
March 9, 2021
ANI Pharmaceuticals completed the acquisition of Novitium Pharma for $163.5 million (including $89.5M cash and $74M equity, plus up to $46.5M in contingent earn-outs), adding a U.S.-based R&D engine and CDMO manufacturing capacity. The deal, financed with a new $300M Term Loan B, a $40M revolver and a $25M PIPE investment from Ampersand Capital Partners, is expected to be immediately accretive and expand ANI's generics, contract manufacturing and 505(b)(2) capabilities.
- Buyers
- ANI Pharmaceuticals, Inc., Ampersand Capital Partners
- Targets
- Novitium Pharma
- Sellers
- Novitium Pharma shareholders (including founders Samy Shanmugam, Chad Gassert and Vijay Thorappadi)
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Angelini Pharma Acquires Catalyst Pharmaceuticals
May 7, 2026
Healthcare Services
Angelini Pharma S.p.A. completed its acquisition of Catalyst Pharmaceuticals, Inc. for an aggregate equity value of approximately $4.1 billion (about €3.5 billion), giving Angelini ownership of Catalyst’s product portfolio and commercial infrastructure. The transaction included participation from funds managed by Blackstone and a €1 billion capital increase approved by CDP Equity, and is part of Angelini Pharma’s expansion into the U.S. brain health and rare disease market.
-
Novartis Acquires Anthos Therapeutics for Up to $3.1B
February 11, 2025
Pharmaceuticals
Blackstone Life Sciences and Anthos Therapeutics announced that Novartis will acquire Anthos for up to $3.1 billion, including a $925 million upfront payment to Anthos shareholders. The deal is expected to close in the first half of 2025, subject to customary closing conditions and regulatory approvals. Novartis later completed the acquisition, valuing the transaction at up to $3.1 billion with the $925 million upfront payment.
-
Novartis Acquires Mariana Oncology
May 2, 2024
Biotechnology
Novartis will acquire Mariana Oncology for $1 billion upfront and up to $750 million in milestone payments, bringing Mariana's peptide-based radiopharmaceutical pipeline and manufacturing capabilities into Novartis. The deal adds radioligand therapeutic discovery, isotope supply chain and manufacturing know-how to Novartis to accelerate development and commercialization of targeted cancer therapies.
-
Novo Nordisk to Acquire Cardior Pharmaceuticals for Up to €1.025 Billion
March 25, 2024
Biotechnology
Novo Nordisk agreed to acquire Cardior Pharmaceuticals for up to €1.025 billion, consisting of an upfront payment plus additional milestone payments tied to development and commercial progress. The deal is expected to strengthen Novo Nordisk’s cardiovascular pipeline, centered on Cardior’s lead candidate CDR132L in phase 2 heart failure trials.
-
ANI Pharmaceuticals Acquires Four ANDAs from Oakrum Pharma, LLC
July 28, 2022
Pharmaceuticals
ANI Pharmaceuticals, Inc. acquired four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC in an asset purchase announced July 28, 2022. The acquisition expands ANI's generics product portfolio and is intended to enable product launches and revenue contribution beginning in 2023.
-
Novacap Acquires PCI Synthesis
June 28, 2018
Pharmaceuticals
Novacap has completed the acquisition of PCI Synthesis, a U.S.-based small-molecule CDMO with R&D and manufacturing sites in Massachusetts. The deal gives Novacap a U.S. footprint and strengthens its global pharmaceutical synthesis and commercial manufacturing capabilities.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.